News
Mean body weight reductions after 24 weeks ranged from 8.2% to 10.3% in the MDR-001 cohorts, versus 2.5% in the placebo arm.
Novo Nordisk A/S is hunting for more early-stage deals to pad its pipeline of next-generation obesity drugs, as the drugmaker ...
Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
A new weight loss pill currently undergoing clinical trials could help burn fat and lower blood sugar levels like Ozempic and ...
GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...
MedPage Today on MSN3d
GLP-1 Drugs Can Be Used First for Weight Loss, Says American College of CardiologyWith semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...
A novel weight loss drug in the same class as semaglutide has successfully met its targets in its largest clinical trial yet, ...
Drugmakers are racing to develop the next wave of obesity and diabetes medications that they hope will be even more powerful ...
Shoppers are buying fewer groceries as the surge in weight-loss jabs hits demand for chocolate, crisps and biscuits. Grocery ...
People started on a low dose of Amgen's long-acting experimental obesity drug MariTide lost as much weight as those given ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback